ZA200708280B - Unit dosage forms of temozolomide - Google Patents

Unit dosage forms of temozolomide

Info

Publication number
ZA200708280B
ZA200708280B ZA200708280A ZA200708280A ZA200708280B ZA 200708280 B ZA200708280 B ZA 200708280B ZA 200708280 A ZA200708280 A ZA 200708280A ZA 200708280 A ZA200708280 A ZA 200708280A ZA 200708280 B ZA200708280 B ZA 200708280B
Authority
ZA
South Africa
Prior art keywords
temozolomide
dosage forms
unit dosage
unit
forms
Prior art date
Application number
ZA200708280A
Other languages
English (en)
Inventor
Bersch Jacqueline Rose
Ramachandra Sumant
Manzo Mark
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA200708280B publication Critical patent/ZA200708280B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ZA200708280A 2006-06-26 2007-09-27 Unit dosage forms of temozolomide ZA200708280B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81662306P 2006-06-26 2006-06-26

Publications (1)

Publication Number Publication Date
ZA200708280B true ZA200708280B (en) 2009-03-25

Family

ID=38704663

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200708280A ZA200708280B (en) 2006-06-26 2007-09-27 Unit dosage forms of temozolomide

Country Status (13)

Country Link
EP (1) EP1901740A2 (pt)
JP (1) JP2008534692A (pt)
KR (2) KR20080015777A (pt)
CN (1) CN101309686A (pt)
AR (1) AR061618A1 (pt)
AU (1) AU2007221979A1 (pt)
BR (1) BRPI0702847A (pt)
CA (1) CA2610439A1 (pt)
CL (1) CL2007001864A1 (pt)
NO (1) NO20074913L (pt)
TW (1) TWI326598B (pt)
WO (1) WO2008002544A2 (pt)
ZA (1) ZA200708280B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526038B (zh) * 2011-01-12 2013-09-11 北京人福军威医药技术开发有限公司 替莫唑胺的脑靶向药物组合物及其应用
US10744171B2 (en) * 2016-03-21 2020-08-18 Duke University Sequential anti-cancer treatment
WO2018167627A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of anti-neoplastic alkylating agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI276434B (en) * 1999-03-30 2007-03-21 Schering Corp Improved cancer treatment with temozolomide
EP1830845A2 (en) * 2004-11-09 2007-09-12 Shering Corporation Improved dosing regimen of temozolomide for treating cancer based on the patient's mgmt level

Also Published As

Publication number Publication date
KR20080015777A (ko) 2008-02-20
CN101309686A (zh) 2008-11-19
BRPI0702847A (pt) 2008-04-01
KR20100055543A (ko) 2010-05-26
WO2008002544A3 (en) 2008-02-07
EP1901740A2 (en) 2008-03-26
WO2008002544A2 (en) 2008-01-03
JP2008534692A (ja) 2008-08-28
CA2610439A1 (en) 2007-12-26
AU2007221979A1 (en) 2008-01-10
AU2007221979A9 (en) 2008-01-10
AR061618A1 (es) 2008-09-10
NO20074913L (no) 2009-03-26
TWI326598B (en) 2010-07-01
CL2007001864A1 (es) 2008-02-08
TW200808803A (en) 2008-02-16

Similar Documents

Publication Publication Date Title
HUS1800011I1 (hu) Kombinációs terápia szubsztituált oxazolidinonokkal
HK1211889A1 (en) Therapeutic use of diaminophenothiazines
EP2068864A4 (en) THERAPEUTIC USES OF UROLITHINS
EP2026843A4 (en) THERAPEUTIC USES OF RTP801L INHIBITORS
HRP20171421T1 (hr) Kruti oblici doziranja bendamustina
GB0610680D0 (en) Therapeutic compounds
GB0603041D0 (en) Therapeutic compounds
EP2035369A4 (en) THERAPEUTIC COMPOUNDS
GB0615809D0 (en) Therapeutic compounds
GB0612971D0 (en) Therapeutic compounds
GB0625349D0 (en) Therapeutic compounds
EP2079704A4 (en) THERAPEUTIC COMPOUNDS
GB0625345D0 (en) Therapeutic compounds
ZA200708280B (en) Unit dosage forms of temozolomide
GB0605573D0 (en) Therapeutic Compounds
GB0603455D0 (en) Therapeutic compounds
HK1156250A1 (en) Unit dosage of apadenoson
GB0608269D0 (en) Therapeutic compounds
IL195722A0 (en) Therapeutic uses of inhibitors of rtp801l
AU2013257527A1 (en) Unit dosage of apadenoson
ZA200806439B (en) Stable dosage formulations of imidazolylalkyl-pyridines
GB0603239D0 (en) Preparation of hydantoins
GB0615907D0 (en) Therapeutic Compounds
GB0610670D0 (en) Therapeutic compounds
GB0614082D0 (en) Therapeutic compounds